secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2026-05-21T20:07:19+00:00
Accession:  0001438533-26-000046
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere shareholders approve 3M share increase under 2018 equity plan
---------------------------------------------------------------------

- Stockholders approved amendment to 2018 Plan, increasing authorized shares by 3,000,000 shares.
- Ten directors elected to serve until 2027 annual meeting; all received majority votes.
- Advisory say-on-pay resolution passed with 73.7M votes for (97.3% of votes cast).
- Shareholders ratified Ernst & Young as independent auditor for fiscal year 2026.
- Annual meeting held May 19, 2026; 81.1M shares (88% of outstanding) were represented.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853326000046/0001438533-26-000046-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853326000046/tvtx-20260519.htm
  HTML page:      https://secwatch.observer/filing/0001438533-26-000046

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer